FDA Accepts Supplemental NDA for Terlivaz by Mallinckrodt
The FDA has accepted a supplemental NDA for Terlivaz (terlipressin acetate) submitted by Mallinckrodt.
Therapeutic Area
Therapeutic area intelligence for Vasopressor with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.